Tekla Capital Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $70.6M | Buy |
247,943
+7,017
| +3% | +$2.09M | 2.76% | 10 |
|
|
2023
Q1 | $67M | Buy |
240,926
+45,496
| +23% | +$12.6M | 2.55% | 12 |
|
|
2022
Q4 | $54.1M | Buy |
195,430
+49,991
| +34% | +$14.1M | 2.04% | 15 |
|
|
2022
Q3 | $38.8M | Buy |
145,439
+9,800
| +7% | +$2.08M | 1.59% | 21 |
|
|
2022
Q2 | $27.7M | Hold |
135,639
| – | – | 1.09% | 27 |
|
|
2022
Q1 | $28.6M | Hold |
135,639
| – | – | 1% | 28 |
|
|
2021
Q4 | $32.5M | Sell |
135,639
-98,214
| -42% | -$25.3M | 1.05% | 27 |
|
|
2021
Q3 | $66.2M | Buy |
233,853
+24,729
| +12% | +$8.1M | 2.13% | 12 |
|
|
2021
Q2 | $72.4M | Sell |
209,124
-37,720
| -15% | -$11.4M | 2.35% | 11 |
|
|
2021
Q1 | $69.1M | Hold |
246,844
| – | – | 2.38% | 10 |
|
|
2020
Q4 | $60.4M | Buy |
246,844
+33,091
| +15% | +$8.54M | 2.12% | 12 |
|
|
2020
Q3 | $60.6M | Sell |
213,753
-19,846
| -8% | -$5.54M | 2.27% | 11 |
|
|
2020
Q2 | $62.5M | Sell |
233,599
-99,136
| -30% | -$29.8M | 2.38% | 9 |
|
|
2020
Q1 | $105M | Buy |
332,735
+47,609
| +17% | +$14.4M | 4.76% | 5 |
|
|
2019
Q4 | $84.6M | Buy |
285,126
+27,187
| +11% | +$7.54M | 3.2% | 7 |
|
|
2019
Q3 | $60.1M | Buy |
257,939
+33,249
| +15% | +$7.74M | 2.62% | 10 |
|
|
2019
Q2 | $52.5M | Sell |
224,690
-89,588
| -29% | -$20.7M | 2.14% | 10 |
|
|
2019
Q1 | $74.3M | Sell |
314,278
-80,624
| -20% | -$25.4M | 3.02% | 9 |
|
|
2018
Q4 | $119M | Buy |
394,902
+3,500
| +0.9% | +$1.12M | 5.09% | 3 |
|
|
2018
Q3 | $138M | Sell |
391,402
-12,553
| -3% | -$4.32M | 5.02% | 3 |
|
|
2018
Q2 | $117M | Buy |
403,955
+25,252
| +7% | +$7.1M | 4.45% | 3 |
|
|
2018
Q1 | $104M | Sell |
378,703
-66,904
| -15% | -$20.8M | 4.03% | 5 |
|
|
2017
Q4 | $142M | Sell |
445,607
-43,997
| -9% | -$14.1M | 5.48% | 4 |
|
|
2017
Q3 | $153M | Sell |
489,604
-40,170
| -8% | -$11.9M | 5.48% | 3 |
|
|
2017
Q2 | $144M | Buy |
529,774
+44,800
| +9% | +$11.8M | 5.33% | 3 |
|
|
2017
Q1 | $133M | Sell |
484,974
-52,376
| -10% | -$14.8M | 5.14% | 3 |
|
|
2016
Q4 | $152M | Buy |
537,350
+55,317
| +11% | +$16.4M | 6.49% | 3 |
|
|
2016
Q3 | $151M | Buy |
482,033
+31,500
| +7% | +$9.33M | 5.8% | 3 |
|
|
2016
Q2 | $109M | Hold |
450,533
| – | – | 4.45% | 3 |
|
|
2016
Q1 | $117M | Hold |
450,533
| – | – | 4.99% | 3 |
|
|
2015
Q4 | $138M | Sell |
450,533
-16,650
| -4% | -$4.78M | 5.01% | 3 |
|
|
2015
Q3 | $136M | Buy |
467,183
+113,950
| +32% | +$37.6M | 4.9% | 3 |
|
|
2015
Q2 | $143M | Buy |
353,233
+13,750
| +4% | +$5.52M | 5.16% | 3 |
|
|
2015
Q1 | $143M | Buy |
339,483
+12,200
| +4% | +$4.81M | 5.68% | 3 |
|
|
2014
Q4 | $111M | Buy |
327,283
+140,500
| +75% | +$45.5M | 5.2% | 3 |
|
|
2014
Q3 | $61.8M | Buy |
186,783
+12,800
| +7% | +$4.22M | 2.9% | 8 |
|
|
2014
Q2 | $54.9M | Hold |
173,983
| – | – | 5.04% | 3 |
|
|
2014
Q1 | $53.2M | Sell |
173,983
-18,000
| -9% | -$5.71M | 5.32% | 5 |
|
|
2013
Q4 | $53.7M | Hold |
191,983
| – | – | 5.64% | 4 |
|
|
2013
Q3 | $46.2M | Hold |
191,983
| – | – | 5.14% | 4 |
|
|
2013
Q2 | $41.3M | Buy |
+191,983
| New | +$41M | 5.62% | 4 |
|
Other funds holding BIIB
Tekla Capital Management's BIIB Position: Q2 2023 in Review
Tekla Capital Management increased its Biogen (BIIB) stake by 2.9% in Q2 2023, buying an estimated $2.09M and bringing the position to 247,943 shares worth $70.6M. The position accounts for 2.76% of the portfolio, ranked #10.
Tekla Capital Management first reported a position in BIIB in Q2 2013 and has held it in 41 quarters since. The position peaked at $153M in Q3 2017. 1,009 funds tracked by Wall St. Rank hold BIIB as of Q2 2023.
- Tekla Capital Management held 247,943 shares of Biogen worth $70.6M as of Q2 2023.
- Tekla Capital Management bought 7,017 Biogen shares in Q2 2023, an estimated $2.09M.
- Biogen made up 2.76% of Tekla Capital Management's portfolio in Q2 2023, its #10 holding.
- Tekla Capital Management first reported a position in Biogen in Q2 2013 and has held it in 41 quarters since.
- Tekla Capital Management's Biogen position peaked at $153M in Q3 2017.
- 1,009 funds tracked by Wall St. Rank held Biogen as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.